大剂量阿托伐他汀对冠心病合并高尿酸血症PCI术后Scr、hsCRP及NGAL的影响

摘要目的：探讨大剂量阿托伐他汀对冠心病合并高尿酸血症PCI术后scr、hsCRP及NGAL的影响。方法：选取2010年6月至2012年6月间于我院接受诊断和治疗的冠心病合并高尿酸血症患者64例，随机分为观察组与对照组，每组32例。观察组给予大剂量阿托伐他汀治疗，对照组给予常规剂量阿托伐他汀治疗。结果：两组患者治疗前Scr、hsCRP及NGAL水平之间相互比较无显著性差异（P〉0．05）。观察组患者术后24hhsCRP水平为（6．7±1．5）m∥L，72hhsCRP水平回落至（5．7±1．0）mg门L，均明显低于对照组（P〈0．05）。观察组患者术后24hNGAL水平为（59．1±12．3）ng／L，72hNGAL水平回落至（47．8±10_3）ngm，均明显低于对照组（P〈0．05）。观察组心脏不良事件发生率明显低于对照组（P〈O．05）。结论：大剂量阿托伐他汀对于冠心病合并高尿酸血症患者PCI术后有一定的肾脏保护作用，且其安全性良好。

The Influence of High-dose Atorvastatin on the Postoperative Level of Scr, hsCRP and NGAL of the Patients with Coronary Heart Disease with Hyperuricemia

Objective： To discuss the influence of high-dose atorvastatin on the postoperative level of Scr, hsCRP and NGAL of the patients with coronary heart disease with hyperuricemia. Method： 64 patients with coronary heart disease with hyperuricemia were selected and randomly divided into the control group and the observation group and each had 32 cases. The patients of the Observation group were given the high-dose atorvastatin while the patients of the control group were given the conventional-dose atorvastatin. Results： The level of Scr, bsCRP and NGAL before treatment made no difference between the two groups （P〉0.05）. The level ofhsCRP 24h after surgery was （6.7± 1.5）mg/L and the level ofhsCRP 72h after surgery was （5.7± 1.0）mg/L. They were both lower than those of the control group （P〈0.05）. The level of NGAL 24h after surgery was （59.1± 12.3）ng/L and the level of NGAL 72h after surgery was （47.8± 10.3）mg/L. They were both lower than those of the control group （P〈0.05）. The incidence of adverse cardiac events of the observation group was obviously lower than that of the control group （P〈0.05）. Conclusion： High-dose atorvastatin on the patients with coronary heart disease with hyperuricemia had Renoprotective effect and a good security.